Shares of Co-Diagnostics plunged 19.7% post-earnings as investors reacted negatively to the cautious outlook and apparent deceleration in key market opportunities, despite ongoing pipeline progress. The market dismissed management’s optimism about regulatory filings and international expansion in favor of near-term commercialization uncertainties.

• Clinical study enrollment for the upper respiratory multiplex test completed with over 1,400 patients, but lower-than-expected COVID prevalence delayed broader submission, now focusing initially on Flu A, Flu B, and RSV only.
• FDA 510(k) submission targeted for Q3 2026, contingent on internal validation and regulatory review, with commercialization still pending.
• Expansion in India via CoSara JV reached regulatory milestones (CDSCO license for local manufacturing) and a larger $13B addressable market, but strategic alternatives including a SPAC remain uncertain with no confirmed transaction.
• TB clinical studies scheduled to begin soon in India, targeting a significant market opportunity but still in early validation stages.
• Progress in Saudi Arabia's CoMira joint venture noted but lacks concrete timelines or near-term revenue impact.